Posted in | News | Nanomedicine

NanGenex Achieves First Milestone for Clinical Development of NanoActive Products

NanGenex Inc. has successfully completed the chemical validation of its latest GMP compliant pilot plant reactor.

This is the first milestone towards fulfilling production needs of the clinical development of NanGenex's NanoActive™ products.

The chemical validation was carried out with active components of two blockbuster drugs. Nanoparticles of cGMP-specific phosphodiesterase type 5 inhibitor and an angiotensin II receptor antagonist drugs were generated with previously set parameters (flow rates, pH, temperature, concentration). These two NanoActive™ Drugs are being commercialized by NanoForm Therapeutics Ltd, London, UK.

During a daily shift the NanoPilot™ reactor can produce 2-4 kilograms actives. Series of tests confirmed that due to the breakthrough design of the equipment, reproducibility is guaranteed and the generated nanoparticles have constant quality. Moreover, the benefits experienced during the production of NanoActives™with the benchtop instruments are also achieved. The nanoparticles from the pilot instrument also demonstrated increased dissolution rate, solubility and bioavailability.

"The importance of this milestone is that we not only created an innovative tool for laboratory use but also established a new industrial scale technology"- said Gabor Heltovics, CEO of NanGenex.

NanGenex is going to present its latest results at the upcoming World Drug Delivery and Formulation 2011 meeting, 17th - 18th January 2011 in Germany.

Source: http://www.nangenex.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Tavanta Therapeutics. (2019, February 12). NanGenex Achieves First Milestone for Clinical Development of NanoActive Products. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=21188.

  • MLA

    Tavanta Therapeutics. "NanGenex Achieves First Milestone for Clinical Development of NanoActive Products". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=21188>.

  • Chicago

    Tavanta Therapeutics. "NanGenex Achieves First Milestone for Clinical Development of NanoActive Products". AZoNano. https://www.azonano.com/news.aspx?newsID=21188. (accessed December 04, 2024).

  • Harvard

    Tavanta Therapeutics. 2019. NanGenex Achieves First Milestone for Clinical Development of NanoActive Products. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=21188.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.